The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Early, Aggressive Therapy for RA May Result in Cost Savings Long Term

Early, Aggressive Therapy for RA May Result in Cost Savings Long Term

August 31, 2015 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Kyu Oh_iStockphoto_money500x270When deciding on therapy for a chronic disease, physicians typically attempt to consider both the short-term and long-term effects. Although the short-term effects are often relatively easy to anticipate, long-term effects are more difficult. Moreover, many clinical studies and cost-effectiveness models include only the short-term effects of therapy, meaning that physicians are missing important data as they make their treatment decisions.

You Might Also Like
  • Effectiveness of Tofacitinib with Methotrexate, Adalimumab Therapy Evaluated in Patients with RA
  • Biosimilars Debate Heats up over Cost Savings, Safety Concerns
  • The Biosimilars Debate Heats Up: Potential cost savings weighed against patient health & safety
Also By This Author
  • AMP RA/Lupus Network Shares Its Progress

In the case of rheumatoid arthritis (RA), physicians and patients seek long-term benefits, such as prevention or slowing of the radiographic progression of RA. However, absent data on long-term benefits, physicians typically prescribe for the short term. For example, in the United Kingdom (UK), patients who are diagnosed with RA are prescribed an initial therapy with a disease-modifying antirheumatic drug (DMARD), such as methotrexate, and then are later offered biologic drugs. The switch to biologics occurs only after a period of time and only if the patient does not respond to DMARDs. Researchers are now questioning this strategy and asking if there is a better way to model the long-term effects of therapy.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Stephanie Stephens, MSc, Director Health Economics & Outcomes Research at Pharmerit Ltd. in the UK, and colleagues modeled the short- and long-term effects of methotrexate (MTX) compared with a combination therapy of MTX plus adalimumab. They published the results of their cost-effectiveness model of patients with early RA online June 9, 2015, in BMJ Open.1 The researchers designed their model to create a unifying view of both short-term and long-term outcomes. The model also attempts to integrate both the reversible and irreversible effects of RA. The investigators based the model on data from patients from the PREMIER trial who were classified as having early, aggressive RA. The model was also based on clinical pathways (DMARDs followed by biologics) typically used to treat RA in the UK.

Stephens and colleagues found that the combination of adalimumab with MTX is a good initial treatment strategy for early, aggressive RA. Specifically, the investigators estimated that combination therapy produced six-month ACR50 responses in 75% of patients. By contrast, only 54% of patients in the MTX-only group achieved a six-month ACR50 response. When compared with MTX mono-therapy, combination therapy resulted in a gain of 2.68 discounted life-years and 3.04 quality-adjusted life-years (QALY).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The combination therapy was cost effective when irreversible damage was included in the calculation. Specifically, the combination therapy resulted in a net increase in direct costs of £106,207, which translated into an incremental cost/QALY gain of £32,425. When the researchers included such indirect costs as a UK societal perspective, the incremental cost-effectiveness ratio (ICER) on combination therapy decreased to £27,238/QALY gained. When the investigators disregarded irreversible effects and included only direct costs, the incremental cost-effectiveness ratio increased to £78,809.

Pages: 1 2 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: adalimumab, combination therapy, DMARDs, healthcare cost, metho­trexate, Rheumatiod arthritis

You Might Also Like:
  • Effectiveness of Tofacitinib with Methotrexate, Adalimumab Therapy Evaluated in Patients with RA
  • Biosimilars Debate Heats up over Cost Savings, Safety Concerns
  • The Biosimilars Debate Heats Up: Potential cost savings weighed against patient health & safety
  • The ACR’s State-of-the-Art Clinical Symposium: Patients with Scleroderma, Lung Disease May Benefit from Aggressive Therapy

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.